Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Novo Nordisk · Phase 3 · Completed · Enrollment 512

NCT05649137

EudraCT 2022-002235-60

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 7.2 mgn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Semaglutide 7.2 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Placebo: endpoint not reported